Next act for BeiGene’s tislelizumab: a Leap deal for gastric cancer

Fresh off the approval of tislelizumab in China, BeiGene has partnered with Leap to pair the PD-1 inhibitor with the latter’s DKK1 inhibitor to create a combination therapy that could help treat cancers that don’t respond to checkpoint inhibitors, such as gastric cancer.

BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) will pay $3 million up front for an exclusive option to DKN-01 in Asia outside of Japan, as

Read the full 646 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers